Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.
Abbas R, Hug BA, Leister C, Sonnichsen D. Abbas R, et al. Among authors: sonnichsen d. Cancer Chemother Pharmacol. 2012 Jul;70(1):191-9. doi: 10.1007/s00280-012-1857-3. Epub 2012 Mar 15. Cancer Chemother Pharmacol. 2012. PMID: 22418773 Clinical Trial.
39 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page